<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04345783</url>
  </required_header>
  <id_info>
    <org_study_id>BFH-CamrelizumabCombo3</org_study_id>
    <nct_id>NCT04345783</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric Cancer</brief_title>
  <official_title>A Study on the Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single-center, single-arm, open-label clinical study, aiming at
      evaluating the efficacy and safety of camrelizumab for injection, apatinib mesylate and tegio
      for first-line refractory patients with advanced gastric cancer.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DFS</measure>
    <time_frame>3 years</time_frame>
    <description>disease free survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OS</measure>
    <time_frame>3 years</time_frame>
    <description>overall survival</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Camrelizumab+Apatinib Mesylate+Tegio</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab for injection, apatinib mesylate and tegio</intervention_name>
    <description>Camrelizumab for injection: fixed dose of 200 mg, ivgtt for 30 minutes, given on D1, repeat for every 3 weeks; Apatinib mesylate: 250 mg, p.o, qd; Tegio capsule: p.o., bid, D1-14, repeat for every 21 days.</description>
    <arm_group_label>Camrelizumab+Apatinib Mesylate+Tegio</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Aged 18-75;

          -  2. ECOG score 0-2;

          -  3. Pathologically diagnosed late-stage adenocarcinoma of stomach or gastroesophageal
             junction, with extra-gastric measurable lesions (spiral CT scan≥10 mm, meeting RECIST
             1.1 criteria);

          -  4. Patients with locally advanced or metastatic gastric or gastroesophageal junction
             adenocarcinoma that are refractory to first-line chemotherapy;

          -  5. Patients who received no previous treatment with apatinib or other VEGFR
             inhibitors, e.g. sorafenib and sunitinib;

          -  6. Normal blood routine examination: Neutrophil count ≥ 1.5 × 109 / L; Hemoglobin ≥ 80
             g / L; Platelet count ≥ 100 × 109 / L; Total bilirubin ≤ 1.5 × ULN; ALT, AST≤2.5×ULN；

          -  7. Without severe dysfunction of heart, lung, liver or kidney, without jaundice and
             digestive tract obstruction, and without acute infection.

        Exclusion Criteria:

          -  1. KPS &lt; 60, or estimated survival &lt; 3 months;

          -  2. Patients with cardiovascular and cerebrovascular events within half a year;
             patients with uncontrollable hypertension (systolic pressure &gt; 140 mmHg, diastolic
             pressure &gt; 90 mmHg), coronary heart disease above grade I, arrhythmia (including QTc
             interval prolongation &gt; 450 ms in men, 470 MS in women) and grade I cardiac
             dysfunction; patients positive of urine albumin;

          -  3. Patients with definite tendency of gastrointestinal bleeding, local active ulcer
             focus, and occult blood in stool (+ +); patients with history of black stool and
             hematemesis within 2 months;

          -  4. Abnormal coagulation (INR &gt; 1.5, APTT &gt; 1.5 ULN), with bleeding tendency;

          -  5. Patients with factors that can affect the absorption of oral-intake drugs (such as
             inability to swallow, nausea, vomiting, chronic diarrhea and intestinal obstruction,
             etc.);

          -  6. Patients with nervous and mental diseases or with severe infection;

          -  7. Pregnant or lactating women or those who have fertility requirements during the
             study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Deng, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Friendship Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 12, 2020</study_first_submitted>
  <study_first_submitted_qc>April 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2020</study_first_posted>
  <last_update_submitted>April 12, 2020</last_update_submitted>
  <last_update_submitted_qc>April 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Zhongtao Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>from 2022.12 on</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

